Creative Medical Technology Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Creative Medical Technology Holdings wird ein Gewinn- und Umsatzwachstum von 72.7% bzw. 86.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 63.3% pro Jahr wachsen soll.

Wichtige Informationen

72.7%

Wachstumsrate der Gewinne

63.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	86.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CELZ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-6	N/A	N/A	1
12/31/2025	N/A	-4	N/A	N/A	1
12/31/2024	N/A	-5	N/A	N/A	1
9/30/2024	0	-5	-5	-5	N/A
6/30/2024	0	-6	-6	-6	N/A
3/31/2024	0	-5	-5	-5	N/A
12/31/2023	0	-5	-8	-8	N/A
9/30/2023	0	-10	-10	-10	N/A
6/30/2023	0	-9	-9	-9	N/A
3/31/2023	0	-10	-10	-10	N/A
12/31/2022	0	-10	-8	-8	N/A
9/30/2022	0	-8	-5	-5	N/A
6/30/2022	0	-9	-5	-5	N/A
3/31/2022	0	-10	-3	-3	N/A
12/31/2021	0	19	-2	-2	N/A
9/30/2021	0	-16	-1	-1	N/A
6/30/2021	0	-13	-1	-1	N/A
3/31/2021	0	-12	-1	-1	N/A
12/31/2020	0	-36	-1	0	N/A
9/30/2020	0	-3	-1	-1	N/A
6/30/2020	0	-6	-1	-1	N/A
3/31/2020	0	-4	-1	-1	N/A
12/31/2019	0	-8	-1	-1	N/A
9/30/2019	0	-1	-1	-1	N/A
6/30/2019	0	-1	-1	-1	N/A
3/31/2019	0	-7	-1	-1	N/A
12/31/2018	0	-14	-1	-1	N/A
9/30/2018	0	-17	-1	-1	N/A
6/30/2018	0	-16	N/A	-1	N/A
3/31/2018	0	-10	N/A	-1	N/A
12/31/2017	0	-3	N/A	-1	N/A
9/30/2017	N/A	-1	N/A	-1	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	N/A	-1	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CELZ wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: CELZ wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CELZ wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CELZ wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CELZ wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CELZ in 3 Jahren voraussichtlich hoch sein wird

Creative Medical Technology Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

New minor risk - Shareholder dilution

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

New minor risk - Share price stability

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem

New major risk - Financial position

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain

Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing Requirements

Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform

Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot Study

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Receives Non-Compliance Notice from Nasdaq

Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in funding

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

High number of new and inexperienced directors

Creative Medical Technology Holdings Deleted from Other OTC

Less than half of directors are independent

Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in funding

Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in funding

Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke Treatment

Creative Medical Technology Holdings, Inc. Announces Fda Acknowledgment of Ind Application for Immcelz® to Treat Stroke

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using Stemspine® Personalized Adult Stem Cell Therapy

Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection Using ImmCelz®

Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented Ovastem® Female Infertility/Ovarian Failure Treatment

Creative Medical Technology Holdings, Inc. Announces the Recruitment of Dr. Caigan Du to the Scientific Advisory Board

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of Immcelz® Therapeutic Activity

Creative Medical Technology Holdings Inc. Recruits Dr. Boris Reznik to the Scientific Advisory Board

Creative Medical Technology Holdings Inc. Files Investigational New Drug Application with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Patent Filing Based on Preclinical Data in Model of Heart Attack Using ImmCelz Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke

Creative Medical Technology Holdings Files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken